Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate

• Clinical data presented at the AACR meeting supports a differentiated safety profile for ELU001 in patients with solid tumors
• No evidence of interstitial lung disease, peripheral neuropathy, liver, kidney, cardiac or ocular adverse events
• Efficacy data from dose escalation and expansion studies anticipated in 2023
• New preclinical data demonstrates potential ability of ELU001 to also treat brain metastases

Excerpt from the Press Release:

MONMOUTH JUNCTION, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, presented positive initial safety data from Phase 1 dose escalation trial of ELU001 (NCT05001282) in a poster titled “ELU-FRα-1: A Study to Evaluate ELU001, a C’Dot Drug Conjugate, in Patients with Solid Tumors that Overexpress Folate Receptor Alpha (FRα)” (abstract #CT255) at the American Association for Cancer Research (AACR) 2023 Annual Meeting. In addition, the company presented new preclinical data in a poster titled “Preclinical development of ELU001 – a folate receptor alpha (FRα)-targeted C’Dot drug conjugate (CDC) for the treatment of brain metastases” (abstract #837).

“We are excited to present, for the first time, safety data from our ongoing Phase 1 clinical trial of ELU001, an FRα targeting C’Dot drug conjugate with an exatecan payload for the treatment of refractory solid tumors. The data highlights the differentiated safety profile, with avoidance of many of the normal tissue toxicities associated with antibody drug conjugates targeting FRα as well as those using a topoisomerase 1 payload” stated Geno Germano, President and CEO of Elucida Oncology. “Our ultra-small CDCs are further differentiated from antibody drug conjugates by their ability to penetrate deep into solid tumors, delivery of high concentrations of drug payload, and binding to cancer cells with high avidity. In addition, the avoidance of uptake into healthy tissue and efficient renal elimination reduces the potential for off target toxicities.”

“Data on two different dosing schedules demonstrates an ELU001 safety profile with side-effects confined to predictable, manageable, and reversible hematologic and gastrointestinal adverse events consistent with its exatecan payload. Importantly, there has been no evidence of interstitial lung disease, peripheral neuropathy, or ocular, liver, renal or cardiac toxicities observed to date.

Click the button below to read the entire Press Release:

Continue Reading The Press Release